Sarah Cannon Research Institute prospective trial published in Journal of Clinical Oncology demonstrates value of molecular profiling in management of metastatic cancer SAN DIEGO--(BUSINESS WIRE)-- A ...

SAN DIEGO, March 19, 2018 /PRNewswire/ -- Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of ...

San Diego, CA, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of a new study evaluating CancerTYPE ID® and its role in identifying subsets of patients with Cancer of ...

Biotheranostics, Inc., announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. CancerTYPE ID helps with identification of tumor type and subtype when a diagnosis remains unclear ...

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)--Biotheranostics, Inc., a pioneer in molecular diagnostics for cancer, and Syapse, the leader in precision medicine software, announce plans to integrate ...

SAN DIEGO, July 27, 2011 /PRNewswire/ --bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today study results ...

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, today announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s ...

THEROS CancerTYPE ID test is designed to identify the primary cancer in patients with metastatic disease. Ferrer InCode negotiated an exclusive, three-year deal to commercialize bioTheranostics’ ...

Biotheranostics, Inc. announces new data from studies for both of its proprietary molecular diagnostic tests, CancerTYPE ID and Breast Cancer Index (BCI) to be presented on Saturday, June 2nd and ...

bioThernostics, a commercial-stage molecular diagnostics company that provides diagnostic, prognostic and predictive tests to support physicians in the treatment of cancer patients, has announced that ...

A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease This retrospective analysis ...